|
Pancreatic Ductal Adenocarcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
QRT-PCR demonstrated increased GPC1 mRNA levels in pancreatic ductal adenocarcinoma (PDAC) compared to normal pancreatic tissues (NPT), as described previously.
|
17016645 |
2006 |
|
Pancreatic Ductal Adenocarcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Glypican-1 (GPC1) is expressed in pancreatic ductal adenocarcinoma (PDAC) cells and adjacent stromal fibroblasts.
|
29721179 |
2018 |
|
Pancreatic Ductal Adenocarcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.
|
28440066 |
2017 |
|
Pancreatic Ductal Adenocarcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDAC<sup>EV</sup> signature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%).
|
28539469 |
2017 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
The use of MIL-38 to detect GPC-1 by IFA discriminated between prostate cancer and BPH urine specimens with a sensitivity and specificity of 71% and 76%, respectively.
|
29672570 |
2018 |
|
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our findings strongly promote future investigation into the use of glypican-1 for early detection of prostate cancer.
|
29854284 |
2018 |
|
Malignant neoplasm of prostate
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Quantification of GPC-1 level is also pivotal to breast cancer and prostate cancer's patients.
|
30202003 |
2018 |
|
Malignant neoplasm of prostate
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We observed high expression of GPC-1 in more aggressive prostate cancer cell lines such as PC-3 and DU-145.
|
31391540 |
2019 |
|
Malignant neoplasm of prostate
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Serum GPC1 levels in PDAC were different from those in gallbladder carcinoma (P < 0.001), colorectal carcinoma (P < 0.001), gastric carcinoma (P < 0.001), and prostate cancer (P < 0.001), but not hepatocellular carcinoma (P = 0.395) and cholangiocarcinoma (P = 0.724).
|
30358133 |
2018 |
|
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Serum GPC1 levels in PDAC were different from those in gallbladder carcinoma (P < 0.001), colorectal carcinoma (P < 0.001), gastric carcinoma (P < 0.001), and prostate cancer (P < 0.001), but not hepatocellular carcinoma (P = 0.395) and cholangiocarcinoma (P = 0.724).
|
30358133 |
2018 |
|
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Quantification of GPC-1 level is also pivotal to breast cancer and prostate cancer's patients.
|
30202003 |
2018 |
|
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We observed high expression of GPC-1 in more aggressive prostate cancer cell lines such as PC-3 and DU-145.
|
31391540 |
2019 |
|
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our findings strongly promote future investigation into the use of glypican-1 for early detection of prostate cancer.
|
29854284 |
2018 |
|
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The use of MIL-38 to detect GPC-1 by IFA discriminated between prostate cancer and BPH urine specimens with a sensitivity and specificity of 71% and 76%, respectively.
|
29672570 |
2018 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We conclude that GPC1 can be a biomarker for relapse of stage III CRC and may be involved in EMT activation, invasion, and migration of colorectal cancer cells.
|
29254156 |
2017 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Serum GPC1 levels in PDAC were different from those in gallbladder carcinoma (P < 0.001), colorectal carcinoma (P < 0.001), gastric carcinoma (P < 0.001), and prostate cancer (P < 0.001), but not hepatocellular carcinoma (P = 0.395) and cholangiocarcinoma (P = 0.724).
|
30358133 |
2018 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The percentage of GPC1<sup>+</sup> exosomes and the GPC1 protein expression in exosomes from tumour tissues and plasma of CRC patients before surgical treatment was significantly elevated compared to that in the peritumoural tissues and the plasma of healthy controls. miR-96-5p and miR-149 expression in tumour tissues and plasma of CRC patients as well as in the GPC1<sup>+</sup> exosomes from CRC patients were significantly decreased compared to that in the peritumoural tissues and the plasma of healthy controls.
|
28233416 |
2017 |
|
Pancreatic Neoplasm
|
0.030 |
Biomarker
|
disease |
LHGDN |
Glypican-1 antisense transfection modulates TGF-beta-dependent signaling in Colo-357 pancreatic cancer cells.
|
15249209 |
2004 |
|
Pancreatic Neoplasm
|
0.030 |
AlteredExpression
|
disease |
LHGDN |
Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma.
|
17016645 |
2006 |
|
Pancreatic Neoplasm
|
0.030 |
Biomarker
|
disease |
BEFREE |
In vivo studies showed that ORI-GPC1-NPs enabled multimodal imaging and targeted therapy in pancreatic tumor xenografted mice.
|
30425490 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.030 |
Biomarker
|
disease |
BEFREE |
The clinicopathological characteristics of GPC1 were evaluated by immunohistochemistry using ESCC specimens, and clinical parameters were assessed.
|
27310703 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.030 |
Biomarker
|
disease |
BEFREE |
Furthermore, anti-GPC1 mAb showed a significant tumor growth inhibition with decreased angiogenesis compared with IgG treated controls in ESCC xenografted mice.
|
28445969 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our study indicated that GPC1 promotes the aggressive proliferation of ESCC cells by regulating the PTEN/Akt/β-catenin pathway.
|
30730015 |
2019 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Quantification of GPC-1 level is also pivotal to breast cancer and prostate cancer's patients.
|
30202003 |
2018 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
α3(V) chains are produced in both basal-like and luminal human breast tumours, and its expression levels are tightly coupled with those of glypican-1 across breast cancer types.
|
28102194 |
2017 |